ALKS (Alkermes) Stock Based Compensation: $112 Mil (TTM As of Mar. 2026)


ALKS Alkermes PLC ALKS
64 GF Score
Price $55.23
GF Value $31.63
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Alkermes Stock Based Compensation?

Alkermes ALKS +0.16% 64 Stock Based Compensation is $112 Mil as of Mar. 2026. GuruFocus rates ALKS with a GF Score™ of 64/100 and a GF Value™ of $31.63 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Alkermes's Stock Based Compensation for the three months ended in Mar. 2026 was $36 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was $112 Mil.

Alkermes Stock Based Compensation Related Terms

Alkermes Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Alkermes's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alkermes Stock Based Compensation Chart

Alkermes Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 87.62 94.25 100.91 96.64 98.72

Alkermes Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.81 24.97 24.67 26.28 36.33
ALKS
64GF Score
Alkermes PLC ALKS
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alkermes Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $112 Mil.

What does a Stock Based Compensation of $112 Mil mean?
Alkermes (ALKS) has a Stock Based Compensation of $112 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Alkermes and its competitors.
Is Alkermes' Stock Based Compensation too high?
Alkermes' current Stock Based Compensation is $112 Mil. Overall, Alkermes has a GF Score™ of 64/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alkermes' Stock Based Compensation compare to HIMS and LNTH?
Alkermes' Stock Based Compensation of $112 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Drug Manufacturers company?
A good Stock Based Compensation depends on the Drug Manufacturers industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Alkermes and its competitors. Alkermes's current Stock Based Compensation is $112 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alkermes stock overvalued right now?
Based on GuruFocus' analysis, Alkermes (ALKS) is currently considered Significantly Overvalued. The stock's GF Value™ is $31.63, compared to a current price of $55.23 — trading 74.6% above its estimated fair value. The current Stock Based Compensation is $112 Mil. Alkermes' overall GF Score™ is 64/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Alkermes (ALKS), the current Stock Based Compensation is $112 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alkermes (ALKS) Overvalued in 2026?

Based on GuruFocus' analysis, Alkermes stock appears to be overvalued. The current stock price of $55.23 is trading 74.6% above its estimated GF Value™ of $31.63. GuruFocus considers Alkermes to be Significantly Overvalued.

Key valuation signals for ALKS:

  • Stock Based Compensation: $112 Mil
  • GF Value™: $31.63 vs. price of $55.23 (74.6% above fair value)
  • GF Score™: 64/100 with 8 warning signs

No single metric tells the full story. See the ALKS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alkermes Business Description

Other Exchanges 8AK:Germany
Address 1 Burlington Road, Connaught House, Dublin, IRL, D04 C5Y6
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
64GF Score

Get the complete analysis for ALKS

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$55.23
Price
$31.63
GF Value